Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, as monotherapy or in combination with durvalumab, in advanced solid tumors to be presented by partner AstraZeneca Preclinical data...Innate Pharma Reports Third Quarter Financial Results
Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab...Innate Pharma announces conference call and webcast for third quarter 2022 business update
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Monday, November 14, 2022, at 2 p.m. CET / 8 a.m. ET...Innate Pharma to present results from a preliminary analysis of the TELLOMAK Phase 2 trial in patients with advanced Sezary syndrome and ANKET platform at ASH 2022
Innate will share preliminary results of the cohort evaluating lacutamab in Sezary syndrome patients post-mogamulizumab from the ongoing TELLOMAK Phase 2 trial Chief Scientific Officer, Eric Vivier...Innate Pharma to participate in upcoming investor conferences
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the following upcoming...Innate Pharma 2023 financial calendar
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2023 financial calendar: March 23, 2023: Publication of 2022 financial statements May 10, 2023...Innate Pharma presents data from ongoing Phase 2 TELLOMAK trial demonstrating clinical activity of lacutamab in advanced mycosis fungoides
Preliminary data set presented at EORTC CLTG annual meeting confirms clinical activity and favorable safety profile of lacutamab in patients with mycosis fungoides who express KIR3DL2 and who were...Innate Pharma reports first half 2022 financial results and business update
Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset based on...Innate Pharma announces conference call and webcast for first half 2022 business update
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 15, 2022, at 2 p.m. CEST / 8 a.m...Innate Pharma to present lacutamab PTCL Phase 1b design and ANKET platform at ESMO 2022
Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK...
